Intellia Therapeutics (NASDAQ:NTLA) had its price target raised by stock analysts at Barclays from $33.00 to $46.00 in a research report issued on Wednesday, March 7th. The brokerage presently has an “overweight” rating on the stock. Barclays’ price target points to a potential upside of 58.08% from the company’s current price.
A number of other research analysts also recently commented on NTLA. TheStreet downgraded Intellia Therapeutics from a “c-” rating to a “d” rating in a research note on Thursday, December 14th. BidaskClub downgraded Intellia Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, December 15th. ValuEngine downgraded Intellia Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, November 15th. Finally, Oppenheimer reaffirmed a “hold” rating on shares of Intellia Therapeutics in a research note on Monday, December 18th. One analyst has rated the stock with a sell rating, four have assigned a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $33.00.
Intellia Therapeutics (NTLA) traded down $4.12 during mid-day trading on Wednesday, reaching $29.10. 4,243,524 shares of the company’s stock were exchanged, compared to its average volume of 1,015,132. Intellia Therapeutics has a 1 year low of $11.15 and a 1 year high of $35.99. The company has a market capitalization of $1,220.00 and a PE ratio of -18.66.
Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings data on Wednesday, March 14th. The company reported ($0.61) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.45) by ($0.16). The company had revenue of $6.70 million for the quarter, compared to the consensus estimate of $8.84 million. Intellia Therapeutics had a negative return on equity of 28.01% and a negative net margin of 215.92%. The company’s revenue for the quarter was up 19.6% compared to the same quarter last year. During the same period last year, the firm earned ($0.31) earnings per share. analysts expect that Intellia Therapeutics will post -1.73 earnings per share for the current fiscal year.
In related news, major shareholder Caribou Biosciences, Inc. sold 550,645 shares of the company’s stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $26.78, for a total value of $14,746,273.10. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 12.80% of the company’s stock.
Several institutional investors have recently bought and sold shares of the business. BlackRock Inc. boosted its holdings in shares of Intellia Therapeutics by 1.9% during the 4th quarter. BlackRock Inc. now owns 1,710,947 shares of the company’s stock worth $32,885,000 after buying an additional 31,662 shares in the last quarter. ARK Investment Management LLC boosted its holdings in shares of Intellia Therapeutics by 269.2% during the 4th quarter. ARK Investment Management LLC now owns 1,375,149 shares of the company’s stock worth $26,430,000 after buying an additional 1,002,671 shares in the last quarter. Farallon Capital Management LLC bought a new position in shares of Intellia Therapeutics during the 4th quarter worth approximately $21,911,000. Vanguard Group Inc. boosted its holdings in shares of Intellia Therapeutics by 10.2% during the 2nd quarter. Vanguard Group Inc. now owns 997,288 shares of the company’s stock worth $15,957,000 after buying an additional 92,580 shares in the last quarter. Finally, GMT Capital Corp bought a new position in shares of Intellia Therapeutics during the 3rd quarter worth approximately $8,214,000. Hedge funds and other institutional investors own 68.14% of the company’s stock.
About Intellia Therapeutics
Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.